Jennifer Good
Co-Founder, CEO, President, & Director

We have some legitimate contenders in here. I'm going to tell you in 15 minutes, a quick overview of Trevi. So Trevi, we have a single asset, nalbuphine ER. We are focused in difficult-to-treat chronic cough conditions. For those of you that have been following cough, it's been a difficult area. There's a huge unmet need. I think what we've brought to the space is a differentiated mechanism that not only works peripherally in the lung, but importantly, centrally in the brain. We are the only investigational therapy that's had positive data in both idiopathic pulmonary fibrosis related cough, but also refractory chronic cough. So two big conditions people have been working in.

This is a specialty sales model. We are approaching it with a specialty focus that we can take this to market ourselves. It's got a big sales opportunity here. I'll take you through it, but it's about a $6 billion-plus peak sales opportunity. So our mechanism, this is where it all starts. The drug works not only peripherally in the lung, it works along the spinal cord and the brain stem in the brain. That mediates coughing and breathing. This is the whole cough reflex arc. So being present in that whole pathway is helpful. And to focus on our 2 lead indications of IPF and non-IPF.

So first of all, starting off with IPF. This is a terminal condition. It's about 140,000 patients in the U.S. You probably know there's been a lot of work done around antifibrotics, which essentially slow disease progression. We're focused on the patient, what upsets the patient's lives most drastically. And they talk about